Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20300504 | 0.89 | RAB9A (0.57) | NPC1RAB9AGABRA2GABRB2MAPT | |
| SCHEMBL31420340 | 0.86 | HPGDS (0.55) | NPC1RAB9AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL8341099 | 0.86 | NPC1 (0.59) | NPC1RAB9ALMNAGABRA2GABRB2 | |
| SCHEMBL24303776 | 0.86 | PTGDR2 (0.52) | NPC1RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL4447424 | 0.86 | LMNA (0.58) | NPC1RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL2411096 | 0.86 | HPGDS (0.62) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL2826141 | 0.85 | MAPT (0.46) | NPC1RAB9ALMNAGABRA2GABRB2 | |
| SCHEMBL9034514 | 0.85 | MEN1 (0.57) | NPC1RAB9AGABRA2GABRB2MEN1 | |
| SCHEMBL12571565 | 0.84 | MAPK1 (0.49) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL508225 | 0.84 | MAPT (0.50) | NPC1RAB9ALMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903077-B | Dihydrooxadiazinone compound and application thereof | 上海超阳药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117903077-A | Dihydrooxadiazinon compound and application thereof | 上海超阳药业有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-2155685-B1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20110046137-A1 | Pyrazole Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED | 2011-02-24 | — | — | US | disclosed |
| EP-2155685-A1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138876-A1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| US-7015218-B1 | Amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
| EP-0540614-B1 | 3-(1-SUBSTITUTEDPYRAZOYL)-2-OXINDOLE DERIVATIVES | PFIZER (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0540614-A1 | 3-(1-SUBSTITUTEDPYRAZOYL)-2-OXINDOLE DERIVATIVES. | PFIZER (US) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001684-A1 | 3-(1-SUBSTITUTEDPYRAZOYL)-2-OXINDOLE DERIVATIVES | PFIZER INC. (US) | 1992-02-06 | — | — | WO | disclosed |
| US-5064851-A | Enzyme inhibitors, antiinflammatory | PFIZER INC. (US) | 1991-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046137-A1 | Pyrazole Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX1 | NPC1 1266/4885RAB9A 2601/4885LMNA 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.